Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.

Understanding the structural basis for defects in protein function that underlie protein-based genetic diseases is the fundamental requirement for development of therapies. This situation is epitomized by the cystic fibrosis transmembrane conductance regulator (CFTR)-the gene product known to be defective in CF patients-that appears particularly susceptible to misfolding when its biogenesis is hampered by mutations at critical loci. While the primary CF-related defect in CFTR has been localized to deletion of nucleotide binding fold (NBD1) residue Phe508, an increasing number of mutations (now ca. 1,500) are being associated with CF disease of varying severity. Hundreds of these mutations occur in the CFTR transmembrane domain, the site of the protein's chloride channel. This report summarizes our current knowledge on how mutation-dependent misfolding of the CFTR protein is recognized on the cellular level; how specific types of mutations can contribute to the misfolding process; and describes experimental approaches to detecting and elucidating the structural consequences of CF-phenotypic mutations.

[1]  M. Welsh,et al.  Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties , 1993, Nature.

[2]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[3]  Paul D. Adams,et al.  Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban , 1995, Nature Structural Biology.

[4]  J. Riordan,et al.  Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. , 1994, The Journal of biological chemistry.

[5]  B. Papsin,et al.  Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.

[6]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[7]  D. Engelman,et al.  Helical membrane protein folding, stability, and evolution. , 2000, Annual review of biochemistry.

[8]  F. Collins,et al.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. , 1991, Science.

[9]  Hui Zhang,et al.  Small heat-shock proteins select deltaF508-CFTR for endoplasmic reticulum-associated degradation. , 2007, Molecular biology of the cell.

[10]  C. Deber,et al.  Retention of native-like oligomerization states in transmembrane segment peptides: application to the Escherichia coli aspartate receptor. , 2001, Biochemistry.

[11]  W. Skach,et al.  Biogenesis of CFTR and other Polytopic Membrane Proteins: New Rolesfor the Ribosome-Translocon Complex , 2004, The Journal of Membrane Biology.

[12]  Bernd Bukau,et al.  Substrate specificity of the DnaK chaperone determined by screening cellulose‐bound peptide libraries , 1997, The EMBO journal.

[13]  C. Deber,et al.  Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations. , 2004, Biochemistry.

[14]  Y. Sohma,et al.  G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects , 2007, The Journal of general physiology.

[15]  C. Fan,et al.  Sequential Quality-Control Checkpoints Triage Misfolded Cystic Fibrosis Transmembrane Conductance Regulator , 2006, Cell.

[16]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[17]  P. Thomas,et al.  Alteration of the Cystic Fibrosis Transmembrane Conductance Regulator Folding Pathway , 1996, The Journal of Biological Chemistry.

[18]  D. Cyr,et al.  The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation , 2000, Nature Cell Biology.

[19]  J. Riordan,et al.  COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code , 2004, The Journal of cell biology.

[20]  R Henderson,et al.  Electron-crystallographic refinement of the structure of bacteriorhodopsin. , 1996, Journal of molecular biology.

[21]  I. Braakman,et al.  Folding of CFTR is predominantly cotranslational. , 2005, Molecular cell.

[22]  K. Du,et al.  Destabilization of the Transmembrane Domain Induces Misfolding in a Phenotypic Mutant of Cystic Fibrosis Transmembrane Conductance Regulator* , 2005, Journal of Biological Chemistry.

[23]  Chad A Brautigam,et al.  Side chain and backbone contributions of Phe508 to CFTR folding , 2005, Nature Structural &Molecular Biology.

[24]  J. Rothman,et al.  Peptide-binding specificity of the molecular chaperone BiP , 1991, Nature.

[25]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.

[26]  Karen Hecht,et al.  Aromatic and cation-pi interactions enhance helix-helix association in a membrane environment. , 2007, Biochemistry.

[27]  F. Hartl,et al.  An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator , 1999, The EMBO journal.

[28]  D. Cyr.  Arrest of CFTRΔF508 folding , 2005, Nature Structural &Molecular Biology.

[29]  C. Perrin,et al.  "Strong" hydrogen bonds in chemistry and biology. , 1997, Annual review of physical chemistry.

[30]  R. Kopito,et al.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. , 2002, The Journal of clinical investigation.

[31]  R. Kopito,et al.  A Principal Role for the Proteasome in Endoplasmic Reticulum-associated Degradation of Misfolded Intracellular Cystic Fibrosis Transmembrane Conductance Regulator* , 2002, The Journal of Biological Chemistry.

[32]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[33]  M. Amaral,et al.  The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. , 2002, The Biochemical journal.

[34]  W. Guggino,et al.  CFTR: Domains, Structure, and Function , 1997, Journal of bioenergetics and biomembranes.

[35]  William F. DeGrado,et al.  Asparagine-mediated self-association of a model transmembrane helix , 2000, Nature Structural Biology.

[36]  J. Marshall,et al.  Characterization of the oligosaccharide structures associated with the cystic fibrosis transmembrane conductance regulator. , 2000, Glycobiology.

[37]  The substrate-binding site in the lactose permease of Escherichia coli. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Wakefield,et al.  Efficient Intracellular Processing of the Endogenous Cystic Fibrosis Transmembrane Conductance Regulator in Epithelial Cell Lines* , 2004, Journal of Biological Chemistry.

[39]  J. Riordan,et al.  Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome , 1998, The EMBO journal.

[40]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[41]  A. Rath,et al.  Role of the extracellular loop in the folding of a CFTR transmembrane helical hairpin. , 2007, Biochemistry.

[42]  M. Amaral.  Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease , 2006, Journal of Inherited Metabolic Disease.

[43]  P. Drain,et al.  Derlin-1 Promotes the Efficient Degradation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and CFTR Folding Mutants* , 2006, Journal of Biological Chemistry.

[44]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[45]  S. High,et al.  Role of calnexin in the glycan‐independent quality control of proteolipid protein , 2003, The EMBO journal.

[46]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[47]  G. Lukács,et al.  Cooh-Terminal Truncations Promote Proteasome-Dependent Degradation of Mature Cystic Fibrosis Transmembrane Conductance Regulator from Post-Golgi Compartments , 2001, The Journal of cell biology.

[48]  J. Dötsch,et al.  Functional Characterization of a Novel CFTR Mutation P67S Identified in a Patient with Atypical Cystic Fibrosis , 2007, Cellular Physiology and Biochemistry.

[49]  A. Rath,et al.  Lipid solvation effects contribute to the affinity of Gly-xxx-Gly motif-mediated helix-helix interactions. , 2006, Biochemistry.

[50]  C. Fan,et al.  A foldable CFTRΔF508 biogenic intermediate accumulates upon inhibition of the Hsc70–CHIP E3 ubiquitin ligase , 2004, The Journal of cell biology.

[51]  L. Serrano.  The relationship between sequence and structure in elementary folding units. , 2000, Advances in protein chemistry.

[52]  S Grinstein,et al.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.

[53]  G. Lukács,et al.  Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. , 1998, Nature structural biology.

[54]  L. Tsui,et al.  Identification of the cystic fibrosis gene: chromosome walking and jumping. , 1989, Science.

[55]  L. Tsui,et al.  Multi-ion pore behaviour in the CFTR chloride channel , 1993, Nature.

[56]  S. Sprang,et al.  Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP , 1993, Cell.

[57]  G. Lukács,et al.  Pharmacologic approaches to correcting the basic defect in cystic fibrosis. , 2003, The New England journal of medicine.

[58]  Min Goo Lee,et al.  A protein sequence that can encode native structure by disfavoring alternate conformations , 2002, Nature Structural Biology.

[59]  R. Kopito,et al.  Cotranslational Ubiquitination of Cystic Fibrosis Transmembrane Conductance Regulator in Vitro * , 1998, The Journal of Biological Chemistry.

[60]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[61]  T. Stevens,et al.  Are membrane proteins “inside‐out” proteins? , 1999, Proteins.

[62]  J. Riordan,et al.  Disease-associated Mutations in the Fourth Cytoplasmic Loop of Cystic Fibrosis Transmembrane Conductance Regulator Compromise Biosynthetic Processing and Chloride Channel Activity* , 1996, The Journal of Biological Chemistry.

[63]  J. Clancy,et al.  Mutations in the Amino Terminus of the Cystic Fibrosis Transmembrane Conductance Regulator Enhance Endocytosis* , 2006, Journal of Biological Chemistry.

[64]  W. Nastainczyk,et al.  BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. , 2005, Molecular biology of the cell.

[65]  J Deisenhofer,et al.  X-ray structure analysis of a membrane protein complex. Electron density map at 3 A resolution and a model of the chromophores of the photosynthetic reaction center from Rhodopseudomonas viridis. , 1984, Journal of molecular biology.

[66]  D. Clarke,et al.  The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. , 2004, The Journal of biological chemistry.

[67]  S. M. Kirov,et al.  Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. , 2007, Microbiology.

[68]  J. Riordan,et al.  F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. , 2006, Biochimica et biophysica acta.

[69]  W. Lennarz,et al.  Unraveling the Mechanism of Protein N-Glycosylation* , 2005, Journal of Biological Chemistry.

[70]  R. Kopito,et al.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. , 1994, The Journal of biological chemistry.

[71]  John D. Venable,et al.  Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis , 2006, Cell.

[72]  D. Cyr.  Arrest of CFTRDeltaF508 folding. , 2005, Nature structural & molecular biology.

[73]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[74]  D. Rees,et al.  An Inward-Facing Conformation of a Putative Metal-Chelate-Type ABC Transporter , 2007, Science.

[75]  E. Strickland,et al.  Localization and Suppression of a Kinetic Defect in Cystic Fibrosis Transmembrane Conductance Regulator Folding* , 1997, The Journal of Biological Chemistry.

[76]  A S Verkman,et al.  Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. , 1996, Cell stress & chaperones.

[77]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[78]  M. Amaral,et al.  Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin , 2005, Molecular and Cellular Biology.

[79]  J. Wilson,et al.  The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. Costerton,et al.  Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid Pseudomonas aeruginosa biofilms. , 2005, Microbiology.

[81]  C. Deber,et al.  Missense mutations in transmembrane domains of proteins: Phenotypic propensity of polar residues for human disease , 2004, Proteins.

[82]  P. Cresswell,et al.  Quality control of transmembrane domain assembly in the tetraspanin CD82 , 2001, The EMBO journal.

[83]  Douglas C. Rees,et al.  The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism , 2002, Science.

[84]  Andrei Aleksandrov,et al.  Domain interdependence in the biosynthetic assembly of CFTR. , 2007, Journal of molecular biology.

[85]  J. Riordan,et al.  Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. , 1999, Molecular cell.

[86]  C. Deber,et al.  Interhelical hydrogen bonds in the CFTR membrane domain , 2001, Nature Structural Biology.

[87]  W. Skach,et al.  p97 functions as an auxiliary factor to facilitate TM domain extraction during CFTR ER‐associated degradation , 2006, The EMBO journal.

[88]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.